This is the seventh and last of a series of posts analyzing randomly selected provisions in HR3200, the House Democratic health care restructuring bill. The hope is that through random selection of pages from the House Bill, using the dartboard method, some light will be shed on the otherwise dense House Bill.The page selected for today’s post is page 794 of the House Bill, which is part of Section 1742 – “Prescription Drug Rebates.”  Section 1742 is just over two pages.  This should be easy.  How hard could it be to understand, and who could be against, prescription drug rebates?Section 1742 has two sections, an Additional Rebate for New Formulations of Existing Drugs, and an Increase Minimum Rebate for Single Source Drugs.  One would think this would be simple, but see if you can follow the formula for rebates on new formulations of existing drugs:In the case of a drug that is a line extension [i.e., extended release formulation] of a...(Read Full Post)